Ranitidine Tablets Recalled for Failed Stability Specifications
Mckesson Packaging Services is recalling Ranitidine Tablets 150 mg due to failed stability specifications. The recall affects 17,192 cartons distributed nationwide.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class II. The source text does not report any illnesses, injuries, or specific adverse health consequences, and the hazard is related to stability specifications rather than a known high-risk pathogen or structural defect.
Plain-English summary
Mckesson Packaging Services is recalling Ranitidine Tablets, USP 150 mg, manufactured by Amneal Pharmaceuticals. The recall is due to failed stability specifications. The affected product is prescription-only and is packaged in cartons of 100 tablets (10x10).
The recall involves 17,192 cartons, totaling 1,719,200 tablets. The affected lots are 0113064 (Exp. 03/2018), 0114628 (Exp. 08/2018), 0115189 (Exp. 08/2018), and 0115462 (Exp. 09/2018). The product was distributed nationwide.
Consumers and healthcare providers should stop using the recalled product and return it to the pharmacy or point of purchase. The FDA classifies this recall as Class II, indicating a situation that may cause temporary or medically reversible adverse health consequences.
The recalled product
- Product
- RANITIDINE Tablets, USP 150 mg UD 100 tablets (10x10), RX Only, Manufactured by: Amneal Pharmaceuticals, Hauppauge, NY 11788, NDC 63739-489-10
- Manufacturer
- Mckesson Packaging Services
- Category
- Drug — Prescription Medication
- Hazard
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (4)
- Lots: 0113064 Exp. 03/2018
- 0114628 Exp. 08/2018
- 0115189 Exp. 08/2018
- 0115462 Exp. 09/2018
Distribution
Distributed nationwide across the United States.
Related recalls
Same manufacturer · Mckesson Packaging Services
See all →- LowMcKesson Recalls Diltiazem HCl Extended-Release Capsules Due to Dissolution Failures
FDA (Drugs) · 2018-05-02
- ModerateMcKesson Recalls Diltiazem CD Capsules Due to Dissolution Failures
FDA (Drugs) · 2018-05-02
- ModerateMcKesson Recalls Diltiazem HCl Extended-Release Capsules Due to Dissolution Failures
FDA (Drugs) · 2018-05-02
- ModerateMcKesson Recalls Subpotent Megestrol Acetate Oral Suspension
FDA (Drugs) · 2018-02-14
- LowMcKesson Recalls Propafenone Hydrochloride Tablets for Moisture Content Issues
FDA (Drugs) · 2017-09-13
Same hazard · stability failure
See all →- ModerateApotex Recalls Paxil Tablets for Failed Dissolution and Stability Testing
FDA (Drugs) · 2026-09-02
- ModerateVasocaine lidocaine spray recalled because stability data does not support expiry
FDA (Drugs) · 2026-03-11
- ModerateZone 1 lidocaine cream recalled because stability data does not support expiry
FDA (Drugs) · 2026-03-11
- ModerateZone 2 lidocaine cream recalled because stability data does not support expiry
FDA (Drugs) · 2026-03-11
- ModerateCiclopirox shampoo recalled after failing impurity specifications at eighteen months
FDA (Drugs) · 2025-12-24